First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac

Technical Innovations & Patient Support in Radiation Oncology

卷:22

Katharine Aitken¹  Ali Hosni²  Uffe Bernchou³  Aisling Barry⁴  Petra.S. Kroon⁵  Marcel Nachbar⁶  Helena M. Verkooijen⁶  Tomas M. Janssen⁷  Ina M. Jürgenliemk-Schulz⁸  Marlies.E. Nowee⁸  Filippo Alongi⁹  William A. Hall¹⁰  Simon Boeke¹¹  Hina Saeed¹¹  Tine Schytte¹² 

[1] Corresponding author.;

[2] Department of Clinical Research, University of Southern Denmark, Odense, Denmark;

[3] University of Brescia;

[4] Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Negrar, Verona, Italy;

[5] Department for Radiation Oncology, University Hospital Tübingen, Tübingen, Germany;

[6] Department of Radiation Oncology, Medical College of Wisconsin, United States;

[7] Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;

[8] Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands;

[9] Department of Radiotherapy, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK;

[10] Laboratory of Radiation Physics and Department of Oncology, Odense University Hospital, Odense, Denmark;

[11] Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada;

[12] Section for Biomedical Physics, Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany;

关键词: (3–6): oligometastases;    MR-guided radiotherapy;    SABR;    MR-Linac;    MOMENTUM;   

DOI  :  

来源: DOAJ

【 摘 要 】

Summary: The treatment of oligometastatic disease using MR guidance is an evolving field. Since August 2018 patients are treated on a 1.5 Tesla MR-Linac (MRL). We present current workflows and practice standards from seven institutions for the initial patients treated for lymph node and liver metastases.

【 授权许可】

Unknown